Mark A. Smith
Directeur Technique/Scientifique/R&D chez BRIGHT MINDS BIOSCIENCES INC.
Fortune : - $ au 30/04/2024
Postes actifs de Mark A. Smith
Sociétés | Poste | Début | Fin |
---|---|---|---|
BRIGHT MINDS BIOSCIENCES INC. | Directeur Technique/Scientifique/R&D | 01/12/2022 | - |
Historique de carrière de Mark A. Smith
Anciens postes connus de Mark A. Smith
Sociétés | Poste | Début | Fin |
---|---|---|---|
VISTAGEN THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/06/2016 | 01/12/2022 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01/09/2012 | 01/10/2013 |
ASTRAZENECA PLC | Corporate Officer/Principal | 01/06/2000 | 01/09/2012 |
Formation de Mark A. Smith
Yale University | Graduate Degree |
University of California San Diego | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Royaume-Uni | 3 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
VISTAGEN THERAPEUTICS, INC. | Health Technology |
ASTRAZENECA PLC | Health Technology |
BRIGHT MINDS BIOSCIENCES INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
- Bourse
- Insiders
- Mark A. Smith
- Expérience